Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
10.34
+0.11 (1.03%)
At close: Feb 11, 2026, 4:00 PM EST
10.36
+0.02 (0.24%)
After-hours: Feb 11, 2026, 4:32 PM EST
Design Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
590.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 226.00K | -608.00K | -72.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 282.08M |
| CorMedix | 214.30M |
| Ginkgo Bioworks Holdings | 180.61M |
| MeiraGTx Holdings | 27.42M |
| Evommune | 13.00M |
| ProKidney | 744.00K |
| Altimmune | 20.00K |
DSGN News
- 2 months ago - Design Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 months ago - Design Therapeutics Appoints Justin Gover to Board of Directors - GlobeNewsWire
- 5 months ago - Design Therapeutics, Inc. (DSGN) Presents at Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 6 months ago - Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference - GlobeNewsWire
- 6 months ago - Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 9 months ago - Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 - GlobeNewsWire
- 9 months ago - Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference - GlobeNewsWire